## Leviathan Cannabis Debuts On The CSE 25 Index And Announces New Stock Option Grants

Toronto, Ontario--(Newsfile Corp. - June 20, 2018) - **Leviathan Cannabis Group Inc.** (CSE: EPIC) (the "Company" or "Leviathan") for the first time in its history, has been added to the CSE 25 Index at the close of trading on Friday, June 15, 2018. As a requirement for inclusion in the composite index, a company must fall within the top quartile of eligible securities listed on the CSE.

Martin J. Doane, CEO of **Leviathan**, comments, "It is a major accomplishment at our early stage of development and we appreciate the recognition from the CSE. Both the Board and Management at **Leviathan** are committed to building a unique, world class enterprise for our shareholders."

The CSE Composite Index is a broad indicator of market activity for the Canadian Securities Exchange. With approximately 75% coverage of all equities listed on the CSE, it is a uniquely positioned gauge of the Canadian small cap market. The index provides a distinctly different risk/return profile than the broad Canadian equity market.

## **Stock Option Grants**

**Leviathan** also announces that the board of directors, on June 19, 2018, approved the granting of stock options to certain officers, directors and consultants exercisable for up to 3,000,000 Common Shares at \$2.00 per share. The expiration date for this entire range of options is June 19, 2021.

## **About Leviathan Cannabis**

Leviathan plans on executing a series of strategic acquisitions that extend across all vertical markets in Canada and internationally, to support the Company's proprietary brand strategy. This global reach positions the Company to be a leading multi-jurisdictional medical and recreational cannabis enterprise — one that brings together the best cannabis products, brands and expertise from Canada and around the world. The Leviathan portfolio currently comprises Jekyll+Hyde Brand Builders Inc., a ground-breaking marketing services agency specializing in the cannabis sector, and Woodstock Biomed Inc, a late stage applicant under the ACMPR, which is in the process of retrofitting a substantial greenhouse production facility in Pelham, Ontario.

Please visit www.LeviathanCannabis.com www.WeAreJekyllandHyde.com

For more information, contact:

Rick Rogers Chairman **Leviathan Cannabis Group Inc.** 416.303.9060

Jayne Beckwith Interim CFO **Leviathan Cannabis Group Inc.** 416.806.0591

###

## Notice Regarding Forward Looking Information

Certain statements in this press release are "forward-looking" statements within the meaning of Canadian and United States securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. Forward-looking statements in this press release include, without limitation, that the Company intends to actively pursue acquisitions in Canada, in international markets and its intention to position the Company as a leading multi-jurisdictional medical and recreational cannabis enterprise. Forward-looking statements are generally, but not always, identified by the words "expects", "plans", "anticipates", "in the event", "if", "believes", "assets", "position", "intends", "envisages", "assumes", "recommends", "estimates", "approximate", "projects", "potential", "indicate" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Forward-looking statements are necessarily based upon the current belief, opinions and expectations of management that, while considered reasonable by the Company, are inherently subject to significant litigation, business, economic, competitive, political and social uncertainties and other contingencies. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties and assumptions, including: identifying acquisitions; successfully negotiating a definitive agreement with an acquisition target; the conditions to the acquisition being satisfied or waived; finding partners to complete a transaction; and applicable board, shareholder, stock exchange, court and regulatory, approval of any proposed transaction.

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.